The latest price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) was reported by Canaccord Genuity on February 18, 2025. The analyst firm set a price target for $385.00 expecting ALNY to rise to within 12 months (a possible 53.64% upside). 71 analyst firms have reported ratings in the last year.

The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) was provided by Canaccord Genuity, and Alnylam Pharmaceuticals maintained their buy rating.

The last upgrade for Alnylam Pharmaceuticals Inc happened on August 16, 2024 when Goldman Sachs raised their price target to $370. Goldman Sachs previously had a neutral for Alnylam Pharmaceuticals Inc.

The last downgrade for Alnylam Pharmaceuticals Inc happened on November 12, 2024 when Wolfe Research changed their price target from N/A to N/A for Alnylam Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on February 18, 2025 so you should expect the next rating to be made available sometime around February 18, 2026.

While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a maintained with a price target of $384.00 to $385.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $250.59, which is out of the analyst’s predicted range.